Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + doxorubicin
- Development stage
- Phase 3
- Lead developer
- Bristol Myers Squibb
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Carboplatin + doxorubicin is a combination chemotherapy regimen consisting of two cytotoxic agents used primarily in the treatment of ovarian cancer and other solid tumors. Carboplatin is a platinum-based compound that induces DNA crosslinking and apoptosis by forming covalent bonds with DNA bases, thereby inhibiting DNA replication and transcription. Doxorubicin is an anthracycline antibiotic that intercalates into DNA, inhibits topoisomerase II activity (leading to double-strand breaks), and generates free radicals causing further cellular damage. The combination—often using pegylated liposomal doxorubicin (PLD) for improved tolerability—has demonstrated efficacy in recurrent or relapsed ovarian cancer, particularly in patients who are platinum-sensitive or have progressed on single-agent therapy. This regimen aims to maximize antitumor activity while reducing overlapping toxicities compared to other combinations such as carboplatin with paclitaxel[1][2][3][4].
- Other names
- carboplatin and doxorubicincarboplatin plus doxorubicincarboplatin + liposomal doxorubicinCD regimen
02
Targets
DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on carboplatin + doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + doxorubicin.